.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Cerilliant
QuintilesIMS
Fuji
McKesson
Cipla
McKinsey
Queensland Health
Accenture
Chinese Patent Office

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,051,141

« Back to Dashboard

Summary for Patent: 4,051,141

Title: Thieno[3,2-c]pyridine derivatives
Abstract:Thieno[3,2-c]pyridine derivatives having the formula: ##STR1## in which X is S; R is a phenyl or benzoyl radical optionally substituted with 1-3 halogen atoms or lower alkyl, lower alkoxy, hydroxy or nitro; R.sub.1 is hydrogen, halogen, hydroxy or lower alkyl; R.sub.2 is hydrogen or halogen and n is 1 or 2, and in which the symbols R.sub.1 may be different in each CHR.sub.1 when n is 2; and their pharmaceutically acceptable acid addition salts. Said derivatives are therapeutically useful for their anti-inflammatory, vasodilatator and blood plate aggregation inhibitor action.
Inventor(s): Castaigne; Albert Rene Joseph (Toulouse, FR)
Assignee: Centre d'Etudes pour l'Industrie pharmaceutique (Toulouse, FR)
Application Number:05/660,248
Patent Claim Types:
see list of patent claims
Compound;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,051,141

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France73.03503Feb 1, 1973

International Patent Family for Patent: 4,051,141

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina217629► Subscribe
Austria338261► Subscribe
Austria350570► Subscribe
AustriaA577576► Subscribe
AustriaA67874► Subscribe
Australia1652576► Subscribe
Australia2103677► Subscribe
Australia473141► Subscribe
Australia503800► Subscribe
Australia507645► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Cantor Fitzgerald
Deloitte
US Department of Justice
Teva
Farmers Insurance
Boehringer Ingelheim
Johnson and Johnson
Accenture
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot